Protease and polymerase inhibitors for the treatment of hepatitis C.

摘要: Chronic hepatitis C is among the leading causes of chronic liver disease worldwide, with approximately 170 million people infected. The severity varies from asymptomatic infection to cirrhosis and hepatocellular carcinoma. Recently,advances have been made, combination pegylated interferon (PEG-IFN) ribavirin a sustained virological response (SVR) in 55% cases. In genotypes 2 or 3, SVR rates reach 80%; genotype 1 50%. Furthermore, appears be long lasting, associated probably reduction risk Despite this progress, treatment failure still occurs about half patients. therapy results several side effects high costs. These limitations led important development novel compounds under name specifically targeted antiviral for HCV (STAT-C). Also, considering cost, prediction non-response mandatory. management must include better knowledge viral cycle mechanisms non response. new molecules such as enzyme inhibitors ongoing. aim review summarize obtained STATC: protease polymerase inhibitors.